{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["39(26)"],"submitter":["Saito S"],"funding":["OrbusNeich Medical, Inc"],"pubmed_abstract":["Aims
Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (HARMONEE) (NCT02073565) was a randomized pivotal registration trial of the Combo stent, which combined sirolimus and an abluminal bioabsorbable polymer with a novel endoluminal anti-CD34+ antibody coating designed to capture endothelial progenitor cells (EPC) and promote percutaneous coronary intervention (PCI) site healing.Methods and results
Clinically stabilized PCI subjects were randomized 1:1 to receive Combo or everolimus-eluting stents (EES). Between February 2014 and June 2016, 572 subjects with 675 coronary lesions underwent 1-year angiography and fractional flow reserve, with optical coherence tomography (OCT) in the first 140 patients. The primary clinical endpoint was non-inf"],"journal":["European heart journal"],"pagination":["2460-2468"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6037087"],"repository":["biostudies-literature"],"pubmed_title":["Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome."],"pmcid":["PMC6037087"],"pubmed_authors":["Saito S","Bertolet BD","Al-Khalidi HR","Rothenberg MD","Tasissa G","Morrell D","Okaniwa Y","Bezerra H","Rowland SM","Krucoff MW","Joseph D","Genereux P","Shibata Y","Maehara A","Nakamura S","Mehran R","Kong DF"],"additional_accession":[]},"is_claimable":false,"name":"Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome.","description":"Aims
Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (HARMONEE) (NCT02073565) was a randomized pivotal registration trial of the Combo stent, which combined sirolimus and an abluminal bioabsorbable polymer with a novel endoluminal anti-CD34+ antibody coating designed to capture endothelial progenitor cells (EPC) and promote percutaneous coronary intervention (PCI) site healing.Methods and results
Clinically stabilized PCI subjects were randomized 1:1 to receive Combo or everolimus-eluting stents (EES). Between February 2014 and June 2016, 572 subjects with 675 coronary lesions underwent 1-year angiography and fractional flow reserve, with optical coherence tomography (OCT) in the first 140 patients. The primary clinical endpoint was non-inf","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jul","modification":"2026-05-04T17:26:24.347Z","creation":"2019-03-26T23:46:01Z"},"accession":"S-EPMC6037087","cross_references":{"pubmed":["29931092"],"doi":["10.1093/eurheartj/ehy275"]}}